Lv1
40 积分 2025-12-09 加入
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
1个月前
已完结
Cancer burden and control in China: landscape, trends and challenges
2个月前
已完结
Innovations in HER2-targeted therapy: A comprehensive review of trastuzumab deruxtecan
2个月前
已完结
The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors
2个月前
已完结
48P First-line lorlatinib versus sequential second-generation ALK TKI followed by lorlatinib in advanced ALK-positive non-small cell lung cancer: A real-world cohort study
3个月前
已完结
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
4个月前
已完结
Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?
4个月前
已完结
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
4个月前
已完结
A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer
4个月前
已完结
Lorlatinib vs crizotinib as first-line treatment for advancedALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study
4个月前
已完结
皖公网安备34019202002308
